0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Attenuated Vaccine for Human Rabies Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-28R14935
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Attenuated Vaccine for Human Rabies Market Insights Forecast to 2029
BUY CHAPTERS

Global Attenuated Vaccine for Human Rabies Market Research Report 2025

Code: QYRE-Auto-28R14935
Report
March 2025
Pages:94
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Attenuated Vaccine for Human Rabies Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Attenuated Vaccine for Human Rabies Market

Attenuated Vaccine for Human Rabies Market

The global market for Attenuated Vaccine for Human Rabies was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Attenuated Vaccine for Human Rabies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Attenuated Vaccine for Human Rabies.
The Attenuated Vaccine for Human Rabies market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Attenuated Vaccine for Human Rabies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Attenuated Vaccine for Human Rabies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Attenuated Vaccine for Human Rabies Market Report

Report Metric Details
Report Name Attenuated Vaccine for Human Rabies Market
CAGR 5%
Segment by Type
Segment by Application
  • Hospital
  • Clinic
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AstraZeneca, GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc, Cadila Pharmaceuticals Ltd, Novartis AG, Pfizer Inc, Liaoning Yisheng Biopharmaceutical Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd, Changchun Zhuoyi Biological Co., Ltd, Guangzhou Nuocheng Biological Products Co., Ltd, Ningbo Rongan Biopharmaceutical Co., Ltd, Shandong Yidu Biotechnology Co., Ltd, Chengdu Kanghua Biological Products Co., Ltd, Wuhan Institute of Biological Products Co., Ltd
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Attenuated Vaccine for Human Rabies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Attenuated Vaccine for Human Rabies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Attenuated Vaccine for Human Rabies Market report?

Ans: The main players in the Attenuated Vaccine for Human Rabies Market are AstraZeneca, GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc, Cadila Pharmaceuticals Ltd, Novartis AG, Pfizer Inc, Liaoning Yisheng Biopharmaceutical Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd, Changchun Zhuoyi Biological Co., Ltd, Guangzhou Nuocheng Biological Products Co., Ltd, Ningbo Rongan Biopharmaceutical Co., Ltd, Shandong Yidu Biotechnology Co., Ltd, Chengdu Kanghua Biological Products Co., Ltd, Wuhan Institute of Biological Products Co., Ltd

What are the Application segmentation covered in the Attenuated Vaccine for Human Rabies Market report?

Ans: The Applications covered in the Attenuated Vaccine for Human Rabies Market report are Hospital, Clinic

What are the Type segmentation covered in the Attenuated Vaccine for Human Rabies Market report?

Ans: The Types covered in the Attenuated Vaccine for Human Rabies Market report are Vero Cell, Human Diploid Cell

Recommended Reports

Rabies Vaccine Markets

Influenza & Viral Vaccines

Vaccine Technology Markets

1 Attenuated Vaccine for Human Rabies Market Overview
1.1 Product Definition
1.2 Attenuated Vaccine for Human Rabies by Type
1.2.1 Global Attenuated Vaccine for Human Rabies Market Value Comparison by Type (2024 VS 2031)
1.2.2 Vero Cell
1.2.3 Human Diploid Cell
1.3 Attenuated Vaccine for Human Rabies by Application
1.3.1 Global Attenuated Vaccine for Human Rabies Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Attenuated Vaccine for Human Rabies Market Size Estimates and Forecasts
1.4.1 Global Attenuated Vaccine for Human Rabies Revenue 2020-2031
1.4.2 Global Attenuated Vaccine for Human Rabies Sales 2020-2031
1.4.3 Global Attenuated Vaccine for Human Rabies Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Attenuated Vaccine for Human Rabies Market Competition by Manufacturers
2.1 Global Attenuated Vaccine for Human Rabies Sales Market Share by Manufacturers (2020-2025)
2.2 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Attenuated Vaccine for Human Rabies Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Attenuated Vaccine for Human Rabies, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Attenuated Vaccine for Human Rabies, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Attenuated Vaccine for Human Rabies, Product Type & Application
2.7 Global Key Manufacturers of Attenuated Vaccine for Human Rabies, Date of Enter into This Industry
2.8 Global Attenuated Vaccine for Human Rabies Market Competitive Situation and Trends
2.8.1 Global Attenuated Vaccine for Human Rabies Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Attenuated Vaccine for Human Rabies Players Market Share by Revenue
2.8.3 Global Attenuated Vaccine for Human Rabies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Attenuated Vaccine for Human Rabies Market Scenario by Region
3.1 Global Attenuated Vaccine for Human Rabies Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Attenuated Vaccine for Human Rabies Sales by Region: 2020-2031
3.2.1 Global Attenuated Vaccine for Human Rabies Sales by Region: 2020-2025
3.2.2 Global Attenuated Vaccine for Human Rabies Sales by Region: 2026-2031
3.3 Global Attenuated Vaccine for Human Rabies Revenue by Region: 2020-2031
3.3.1 Global Attenuated Vaccine for Human Rabies Revenue by Region: 2020-2025
3.3.2 Global Attenuated Vaccine for Human Rabies Revenue by Region: 2026-2031
3.4 North America Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
3.4.1 North America Attenuated Vaccine for Human Rabies Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Attenuated Vaccine for Human Rabies Sales by Country (2020-2031)
3.4.3 North America Attenuated Vaccine for Human Rabies Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
3.5.1 Europe Attenuated Vaccine for Human Rabies Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Attenuated Vaccine for Human Rabies Sales by Country (2020-2031)
3.5.3 Europe Attenuated Vaccine for Human Rabies Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Attenuated Vaccine for Human Rabies Market Facts & Figures by Region
3.6.1 Asia Pacific Attenuated Vaccine for Human Rabies Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Attenuated Vaccine for Human Rabies Sales by Region (2020-2031)
3.6.3 Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
3.7.1 Latin America Attenuated Vaccine for Human Rabies Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Attenuated Vaccine for Human Rabies Sales by Country (2020-2031)
3.7.3 Latin America Attenuated Vaccine for Human Rabies Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
3.8.1 Middle East and Africa Attenuated Vaccine for Human Rabies Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2020-2031)
3.8.3 Middle East and Africa Attenuated Vaccine for Human Rabies Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Attenuated Vaccine for Human Rabies Sales by Type (2020-2031)
4.1.1 Global Attenuated Vaccine for Human Rabies Sales by Type (2020-2025)
4.1.2 Global Attenuated Vaccine for Human Rabies Sales by Type (2026-2031)
4.1.3 Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2020-2031)
4.2 Global Attenuated Vaccine for Human Rabies Revenue by Type (2020-2031)
4.2.1 Global Attenuated Vaccine for Human Rabies Revenue by Type (2020-2025)
4.2.2 Global Attenuated Vaccine for Human Rabies Revenue by Type (2026-2031)
4.2.3 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2020-2031)
4.3 Global Attenuated Vaccine for Human Rabies Price by Type (2020-2031)
5 Segment by Application
5.1 Global Attenuated Vaccine for Human Rabies Sales by Application (2020-2031)
5.1.1 Global Attenuated Vaccine for Human Rabies Sales by Application (2020-2025)
5.1.2 Global Attenuated Vaccine for Human Rabies Sales by Application (2026-2031)
5.1.3 Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2020-2031)
5.2 Global Attenuated Vaccine for Human Rabies Revenue by Application (2020-2031)
5.2.1 Global Attenuated Vaccine for Human Rabies Revenue by Application (2020-2025)
5.2.2 Global Attenuated Vaccine for Human Rabies Revenue by Application (2026-2031)
5.2.3 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2020-2031)
5.3 Global Attenuated Vaccine for Human Rabies Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Company Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Merck & Co Inc
6.3.1 Merck & Co Inc Company Information
6.3.2 Merck & Co Inc Description and Business Overview
6.3.3 Merck & Co Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio
6.3.5 Merck & Co Inc Recent Developments/Updates
6.4 Sanofi Pasteur, Inc
6.4.1 Sanofi Pasteur, Inc Company Information
6.4.2 Sanofi Pasteur, Inc Description and Business Overview
6.4.3 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio
6.4.5 Sanofi Pasteur, Inc Recent Developments/Updates
6.5 Cadila Pharmaceuticals Ltd
6.5.1 Cadila Pharmaceuticals Ltd Company Information
6.5.2 Cadila Pharmaceuticals Ltd Description and Business Overview
6.5.3 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.5.5 Cadila Pharmaceuticals Ltd Recent Developments/Updates
6.6 Novartis AG
6.6.1 Novartis AG Company Information
6.6.2 Novartis AG Description and Business Overview
6.6.3 Novartis AG Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio
6.6.5 Novartis AG Recent Developments/Updates
6.7 Pfizer Inc
6.7.1 Pfizer Inc Company Information
6.7.2 Pfizer Inc Description and Business Overview
6.7.3 Pfizer Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio
6.7.5 Pfizer Inc Recent Developments/Updates
6.8 Liaoning Yisheng Biopharmaceutical Co., Ltd
6.8.1 Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information
6.8.2 Liaoning Yisheng Biopharmaceutical Co., Ltd Description and Business Overview
6.8.3 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.8.5 Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Developments/Updates
6.9 Lanzhou Institute of Biological Products Co., Ltd
6.9.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
6.9.2 Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
6.9.3 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.9.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
6.10 Changchun Zhuoyi Biological Co., Ltd
6.10.1 Changchun Zhuoyi Biological Co., Ltd Company Information
6.10.2 Changchun Zhuoyi Biological Co., Ltd Description and Business Overview
6.10.3 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.10.5 Changchun Zhuoyi Biological Co., Ltd Recent Developments/Updates
6.11 Guangzhou Nuocheng Biological Products Co., Ltd
6.11.1 Guangzhou Nuocheng Biological Products Co., Ltd Company Information
6.11.2 Guangzhou Nuocheng Biological Products Co., Ltd Description and Business Overview
6.11.3 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.11.5 Guangzhou Nuocheng Biological Products Co., Ltd Recent Developments/Updates
6.12 Ningbo Rongan Biopharmaceutical Co., Ltd
6.12.1 Ningbo Rongan Biopharmaceutical Co., Ltd Company Information
6.12.2 Ningbo Rongan Biopharmaceutical Co., Ltd Description and Business Overview
6.12.3 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.12.5 Ningbo Rongan Biopharmaceutical Co., Ltd Recent Developments/Updates
6.13 Shandong Yidu Biotechnology Co., Ltd
6.13.1 Shandong Yidu Biotechnology Co., Ltd Company Information
6.13.2 Shandong Yidu Biotechnology Co., Ltd Description and Business Overview
6.13.3 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.13.5 Shandong Yidu Biotechnology Co., Ltd Recent Developments/Updates
6.14 Chengdu Kanghua Biological Products Co., Ltd
6.14.1 Chengdu Kanghua Biological Products Co., Ltd Company Information
6.14.2 Chengdu Kanghua Biological Products Co., Ltd Description and Business Overview
6.14.3 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.14.5 Chengdu Kanghua Biological Products Co., Ltd Recent Developments/Updates
6.15 Wuhan Institute of Biological Products Co., Ltd
6.15.1 Wuhan Institute of Biological Products Co., Ltd Company Information
6.15.2 Wuhan Institute of Biological Products Co., Ltd Description and Business Overview
6.15.3 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.15.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Attenuated Vaccine for Human Rabies Industry Chain Analysis
7.2 Attenuated Vaccine for Human Rabies Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Attenuated Vaccine for Human Rabies Production Mode & Process Analysis
7.4 Attenuated Vaccine for Human Rabies Sales and Marketing
7.4.1 Attenuated Vaccine for Human Rabies Sales Channels
7.4.2 Attenuated Vaccine for Human Rabies Distributors
7.5 Attenuated Vaccine for Human Rabies Customer Analysis
8 Attenuated Vaccine for Human Rabies Market Dynamics
8.1 Attenuated Vaccine for Human Rabies Industry Trends
8.2 Attenuated Vaccine for Human Rabies Market Drivers
8.3 Attenuated Vaccine for Human Rabies Market Challenges
8.4 Attenuated Vaccine for Human Rabies Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Attenuated Vaccine for Human Rabies Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Attenuated Vaccine for Human Rabies Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Attenuated Vaccine for Human Rabies Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Attenuated Vaccine for Human Rabies Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Attenuated Vaccine for Human Rabies Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Attenuated Vaccine for Human Rabies Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Attenuated Vaccine for Human Rabies Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Attenuated Vaccine for Human Rabies Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Attenuated Vaccine for Human Rabies, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Attenuated Vaccine for Human Rabies, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Attenuated Vaccine for Human Rabies, Product Type & Application
 Table 12. Global Key Manufacturers of Attenuated Vaccine for Human Rabies, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Attenuated Vaccine for Human Rabies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attenuated Vaccine for Human Rabies as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Attenuated Vaccine for Human Rabies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Attenuated Vaccine for Human Rabies Sales by Region (2020-2025) & (K Units)
 Table 18. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2020-2025)
 Table 19. Global Attenuated Vaccine for Human Rabies Sales by Region (2026-2031) & (K Units)
 Table 20. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2026-2031)
 Table 21. Global Attenuated Vaccine for Human Rabies Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2020-2025)
 Table 23. Global Attenuated Vaccine for Human Rabies Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2026-2031)
 Table 25. North America Attenuated Vaccine for Human Rabies Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Attenuated Vaccine for Human Rabies Sales by Country (2020-2025) & (K Units)
 Table 27. North America Attenuated Vaccine for Human Rabies Sales by Country (2026-2031) & (K Units)
 Table 28. North America Attenuated Vaccine for Human Rabies Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Attenuated Vaccine for Human Rabies Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Attenuated Vaccine for Human Rabies Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Attenuated Vaccine for Human Rabies Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Attenuated Vaccine for Human Rabies Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Attenuated Vaccine for Human Rabies Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Attenuated Vaccine for Human Rabies Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Attenuated Vaccine for Human Rabies Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Attenuated Vaccine for Human Rabies Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Attenuated Vaccine for Human Rabies Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Attenuated Vaccine for Human Rabies Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Attenuated Vaccine for Human Rabies Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Attenuated Vaccine for Human Rabies Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Attenuated Vaccine for Human Rabies Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Attenuated Vaccine for Human Rabies Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Attenuated Vaccine for Human Rabies Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Attenuated Vaccine for Human Rabies Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Attenuated Vaccine for Human Rabies Sales (K Units) by Type (2020-2025)
 Table 51. Global Attenuated Vaccine for Human Rabies Sales (K Units) by Type (2026-2031)
 Table 52. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2020-2025)
 Table 53. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2026-2031)
 Table 54. Global Attenuated Vaccine for Human Rabies Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Attenuated Vaccine for Human Rabies Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2020-2025)
 Table 57. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2026-2031)
 Table 58. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Attenuated Vaccine for Human Rabies Sales (K Units) by Application (2020-2025)
 Table 61. Global Attenuated Vaccine for Human Rabies Sales (K Units) by Application (2026-2031)
 Table 62. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2020-2025)
 Table 63. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2026-2031)
 Table 64. Global Attenuated Vaccine for Human Rabies Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Attenuated Vaccine for Human Rabies Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2020-2025)
 Table 67. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2026-2031)
 Table 68. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Application (2026-2031)
 Table 70. AstraZeneca Company Information
 Table 71. AstraZeneca Description and Business Overview
 Table 72. AstraZeneca Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. AstraZeneca Attenuated Vaccine for Human Rabies Product
 Table 74. AstraZeneca Recent Developments/Updates
 Table 75. GlaxoSmithKline Company Information
 Table 76. GlaxoSmithKline Description and Business Overview
 Table 77. GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. GlaxoSmithKline Attenuated Vaccine for Human Rabies Product
 Table 79. GlaxoSmithKline Recent Developments/Updates
 Table 80. Merck & Co Inc Company Information
 Table 81. Merck & Co Inc Description and Business Overview
 Table 82. Merck & Co Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Merck & Co Inc Attenuated Vaccine for Human Rabies Product
 Table 84. Merck & Co Inc Recent Developments/Updates
 Table 85. Sanofi Pasteur, Inc Company Information
 Table 86. Sanofi Pasteur, Inc Description and Business Overview
 Table 87. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product
 Table 89. Sanofi Pasteur, Inc Recent Developments/Updates
 Table 90. Cadila Pharmaceuticals Ltd Company Information
 Table 91. Cadila Pharmaceuticals Ltd Description and Business Overview
 Table 92. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product
 Table 94. Cadila Pharmaceuticals Ltd Recent Developments/Updates
 Table 95. Novartis AG Company Information
 Table 96. Novartis AG Description and Business Overview
 Table 97. Novartis AG Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Novartis AG Attenuated Vaccine for Human Rabies Product
 Table 99. Novartis AG Recent Developments/Updates
 Table 100. Pfizer Inc Company Information
 Table 101. Pfizer Inc Description and Business Overview
 Table 102. Pfizer Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Pfizer Inc Attenuated Vaccine for Human Rabies Product
 Table 104. Pfizer Inc Recent Developments/Updates
 Table 105. Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information
 Table 106. Liaoning Yisheng Biopharmaceutical Co., Ltd Description and Business Overview
 Table 107. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product
 Table 109. Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Developments/Updates
 Table 110. Lanzhou Institute of Biological Products Co., Ltd Company Information
 Table 111. Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
 Table 112. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product
 Table 114. Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
 Table 115. Changchun Zhuoyi Biological Co., Ltd Company Information
 Table 116. Changchun Zhuoyi Biological Co., Ltd Description and Business Overview
 Table 117. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product
 Table 119. Changchun Zhuoyi Biological Co., Ltd Recent Developments/Updates
 Table 120. Guangzhou Nuocheng Biological Products Co., Ltd Company Information
 Table 121. Guangzhou Nuocheng Biological Products Co., Ltd Description and Business Overview
 Table 122. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product
 Table 124. Guangzhou Nuocheng Biological Products Co., Ltd Recent Developments/Updates
 Table 125. Ningbo Rongan Biopharmaceutical Co., Ltd Company Information
 Table 126. Ningbo Rongan Biopharmaceutical Co., Ltd Description and Business Overview
 Table 127. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product
 Table 129. Ningbo Rongan Biopharmaceutical Co., Ltd Recent Developments/Updates
 Table 130. Shandong Yidu Biotechnology Co., Ltd Company Information
 Table 131. Shandong Yidu Biotechnology Co., Ltd Description and Business Overview
 Table 132. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product
 Table 134. Shandong Yidu Biotechnology Co., Ltd Recent Developments/Updates
 Table 135. Chengdu Kanghua Biological Products Co., Ltd Company Information
 Table 136. Chengdu Kanghua Biological Products Co., Ltd Description and Business Overview
 Table 137. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product
 Table 139. Chengdu Kanghua Biological Products Co., Ltd Recent Developments/Updates
 Table 140. Wuhan Institute of Biological Products Co., Ltd Company Information
 Table 141. Wuhan Institute of Biological Products Co., Ltd Description and Business Overview
 Table 142. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product
 Table 144. Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
 Table 145. Key Raw Materials Lists
 Table 146. Raw Materials Key Suppliers Lists
 Table 147. Attenuated Vaccine for Human Rabies Distributors List
 Table 148. Attenuated Vaccine for Human Rabies Customers List
 Table 149. Attenuated Vaccine for Human Rabies Market Trends
 Table 150. Attenuated Vaccine for Human Rabies Market Drivers
 Table 151. Attenuated Vaccine for Human Rabies Market Challenges
 Table 152. Attenuated Vaccine for Human Rabies Market Restraints
 Table 153. Research Programs/Design for This Report
 Table 154. Key Data Information from Secondary Sources
 Table 155. Key Data Information from Primary Sources
 Table 156. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Attenuated Vaccine for Human Rabies
 Figure 2. Global Attenuated Vaccine for Human Rabies Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Attenuated Vaccine for Human Rabies Market Share by Type: 2024 & 2031
 Figure 4. Vero Cell Product Picture
 Figure 5. Human Diploid Cell Product Picture
 Figure 6. Global Attenuated Vaccine for Human Rabies Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Attenuated Vaccine for Human Rabies Market Share by Application: 2024 & 2031
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Global Attenuated Vaccine for Human Rabies Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Attenuated Vaccine for Human Rabies Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Attenuated Vaccine for Human Rabies Sales (2020-2031) & (K Units)
 Figure 13. Global Attenuated Vaccine for Human Rabies Average Price (US$/Unit) & (2020-2031)
 Figure 14. Attenuated Vaccine for Human Rabies Report Years Considered
 Figure 15. Attenuated Vaccine for Human Rabies Sales Share by Manufacturers in 2024
 Figure 16. Global Attenuated Vaccine for Human Rabies Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Attenuated Vaccine for Human Rabies Players: Market Share by Revenue in Attenuated Vaccine for Human Rabies in 2024
 Figure 18. Attenuated Vaccine for Human Rabies Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Attenuated Vaccine for Human Rabies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Attenuated Vaccine for Human Rabies Sales Market Share by Country (2020-2031)
 Figure 21. North America Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2020-2031)
 Figure 22. United States Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Country (2020-2031)
 Figure 25. Europe Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Attenuated Vaccine for Human Rabies Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2020-2031)
 Figure 33. China Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. China Taiwan Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Southeast Asia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Latin America Attenuated Vaccine for Human Rabies Sales Market Share by Country (2020-2031)
 Figure 41. Latin America Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2020-2031)
 Figure 42. Mexico Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Brazil Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Argentina Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Middle East and Africa Attenuated Vaccine for Human Rabies Sales Market Share by Country (2020-2031)
 Figure 46. Middle East and Africa Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2020-2031)
 Figure 47. Turkey Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. UAE Attenuated Vaccine for Human Rabies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Global Sales Market Share of Attenuated Vaccine for Human Rabies by Type (2020-2031)
 Figure 51. Global Revenue Market Share of Attenuated Vaccine for Human Rabies by Type (2020-2031)
 Figure 52. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Type (2020-2031)
 Figure 53. Global Sales Market Share of Attenuated Vaccine for Human Rabies by Application (2020-2031)
 Figure 54. Global Revenue Market Share of Attenuated Vaccine for Human Rabies by Application (2020-2031)
 Figure 55. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Application (2020-2031)
 Figure 56. Attenuated Vaccine for Human Rabies Value Chain
 Figure 57. Channels of Distribution (Direct Vs Distribution)
 Figure 58. Bottom-up and Top-down Approaches for This Report
 Figure 59. Data Triangulation
 Figure 60. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS